



131st MAINE LEGISLATURE

FIRST REGULAR SESSION-2023

Legislative Document

No. 663

H.P. 432

House of Representatives, February 16, 2023

An Act to Require Health Insurance Coverage for Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections and Pediatric Acute-onset Neuropsychiatric Syndrome

Reference to the Committee on Health Coverage, Insurance and Financial Services suggested and ordered printed.

R(+ B. Hunt

ROBERT B. HUNT Clerk

Presented by Representative ROEDER of Bangor. Cosponsored by Senator BALDACCI of Penobscot and Representative: RANA of Bangor.

1 Be it enacted by the People of the State of Maine as follows: 2 Sec. 1. 24-A MRSA §4320-V is enacted to read: 3 §4320-V. Coverage for pediatric autoimmune neuropsychiatric disorders associated 4 with streptococcal infections and pediatric acute-onset neuropsychiatric 5 syndrome 6 A carrier offering a health plan in this State shall provide coverage for treatment of 7 pediatric postinfectious neuroimmune disorders including pediatric autoimmune 8 neuropsychiatric disorders associated with streptococcal infections and pediatric acuteonset neuropsychiatric syndrome. Treatments that must be covered include, but are not 9 10 limited to, long-term antibiotics, intravenous immunoglobulin therapy, steroids, plasmapheresis and psychopharmacological interventions. Coverage may not be excluded 11 12 due to the diagnosis of autoimmune encephalopathy or autoimmune encephalitis. 13 Sec. 2. Application. The requirements of this Act apply to all policies, contracts and certificates executed, delivered, issued for delivery, continued or renewed in this State 14 on or after January 1, 2024. For purposes of this Act all contracts are deemed to be renewed 15 16 no later than the next yearly anniversary of the contract date. 17 SUMMARY 18 This bill requires health insurance coverage for treatment of pediatric postinfectious 19 neuroimmune disorders including pediatric autoimmune neuropsychiatric disorders 20 associated with streptococcal infections and pediatric acute-onset neuropsychiatric 21 syndrome. The requirements apply to all individual and group policies and contracts issued 22 or renewed on or after January 1, 2024.